Synthetic cannabinoids and potential cardiac arrhythmia risk : an important message for drug users Jules C. Hancox, Nicola J. Kalk and Graeme Henderson Therapeutic Advances in Drug Safety, 2020, 11, 1-4. Doi : 10.1177/2042098620913416 Δ9-Tetrahydrocannabinol, the psychoactive ingredient in cannabis, and synthetic cannabinoid receptor agonists (SCRAs) activate the CB1 receptor to produce their profound behavioural effects and are widely used as recreational drugs. There is growing evidence that SCRAs, commonly known by the street name Spice or K2 (though there are many others, see: http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids) can produce detrimental cardiovascular effects.(1) Commonly observed cardiotoxic effects of SCRAs include tachycardia, chest pain and hypertension.(1) However, bradycardia and [...]
Lire la suiteA single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study Khalid A. Jadoon, Garry D. Tan, and Saoirse E. O’Sullivan JCI Insight, 2017, 2, (11), e93760 Doi : 10.1172/jci.insight.93760 BACKGROUND. Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate if CBD reduces BP in humans. METHODS. Nine healthy male volunteers were given 600 mg of CBD or placebo in a randomized, placebo-controlled, double-blind, crossover study. Cardiovascular parameters were monitored using [...]
Lire la suite